Navigation Links
The Quantum Group Announces Strategic Technology Alliance
Date:2/26/2008

nal patents discussed in this press release will be granted by the US Patent and Trademark Office, or, if they are granted, they will not be challenged by third parties, or if not that we will be able to effectively use or commercialize such patents and/or we may not have the resources to deploy such technology. As a result, investors should not place undue reliance on these forward-looking statements.

FOR MORE INFORMATION, PLEASE CONTACT:

BPC Financial Marketing

John Baldissera

800.368.1217

Or

Danielle Amodio

Vice President Corporate Communications

The Quantum Group, Inc.

561.798.9800


'/>"/>
SOURCE The Quantum Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. The Quantum Group to Present at the Jesup & Lamont Emerging Growth Stock Conference on February 28th
2. The Quantum Group Reports 4th Quarter and Year End Results for Fiscal Year 2007
3. The Quantum Group, Inc. Announces Separation of Units
4. Results promising for computational quantum chemical methods for drug development
5. The Quantum Group, Inc. Completes $13.2 Million Public Offering and Initiates Trading on the American Stock Exchange Under Symbol QGP
6. American Stock Exchange Lists the Common Stock and Units of The Quantum Group, Inc.
7. Quantum Foundation Makes a Half Million Dollars Available to Federally Qualified Health Centers
8. Quantum light beams good for fast technology
9. The Ensign Group Establishes $50 Million Credit Facility with GE Healthcare Financial Services
10. Vital Health Technologies, Inc. / Caribbean American Health Resorts Inc. Acquires Momentum Medical Group, Inc.
11. Justice Department Requires Divestiture in UnitedHealth Groups Acquisition of Sierra Health Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...most from chemo after surgery, study says , ...f 15 genes may help determine which patients with ...ence a recurrence and, therefore, benefit the most...tension, the same genetic signature may also ident...cer who would be able to forego chemotherapy. ,...
(Date:5/16/2008)...e/ -- As tropical storms,continue to batter the af...yclone Nargis are vulnerable to diseases and other...ance, as exposure to the foul weather and,malnutri... "The people living in these conditions urgently ...et back on their feet," said David Meltzer,senior...
(Date:5/16/2008)... 2007, WASHINGTON, May 16 /PRNewswire-USNewswire/...eaths, the National Cancer Institute (NCI) investe...cancer research in 2007,according to updated stat..., The two other federal agencies with significant...ontrol and Prevention (CDC) and the,Department of ...
(Date:5/16/2008)... -- CryoCor, Inc. (Nasdaq:,CRYO), a medical device...thmias, announced today that on May 8, 2008, two a...plaint in the Superior Court of the State,of Calif...ach member of the,Board of Directors of CryoCor, C...laint is styled Secondido, et al. v. CryoCor, Inc....
Breaking Medicine News(10 mins):Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Myanmar Cyclone Survivors Face New Challenges 2Health News:Lung Cancer Still Lowest in Federal Funding 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 4
...an Saturday in Burhanpur district of Madhya Prades...ng Maharashtra testing positive for the deadly bir...ensation will also be paid to 323 affected poultry...nfected," said Rajesh Rajora, commissioner of the ...
...te University are pumping for a controversial theo...n be forced// into "dark states" where they can be...new idea appears to contravene some of the most ac...eory, not long ago dismissed as impossible by much...
...scovered a second candidate gene - cathepsin B - r...titis disease that leads to a gradual destruction ... progressive destruction of pancreas and a painful...rike people in tropical countries, including India...
...o reconstruct a complex molecular system of Darwin...niques for resurrecting// ancient genes. The re...r of biology at the University of Oregon's Center ...nd will be published in the April 7 issue of SCIEN...
Other Medicine News:Health News:Controversial Theory Says DNA Can Be Pushed To "Dark States" 2Health News:Controversial Theory Says DNA Can Be Pushed To "Dark States" 3Health News:Indian Scientists Identify Second Pancreatitis Gene 2Health News:Scientists Explain Complex Darwinian Evolution 2
(Date:5/15/2008)...mount of research reflects depth and breadth of, ...lop new treatments for dive...ht impact of Zometa(R), the leading IV, bisphospho... breast cancer, - Four oral sessions to feature R... of mTOR, including first results of RECORD-1 stud...
(Date:5/15/2008)...d TOULOUSE, France, May 15 /- Cerenis...aceutical company,developing HDL-related compounds... diseases, today announced that it has completed a...mpany,s lead product candidates.,CER-002 is a pero...a-specific agonist in development for the treatmen...
(Date:5/15/2008)...y Remains for an Antiplatelet Therapy that, Combin...mbination of Plavix/Iscover and Aspirin, Accor...THAM, Mass., May 15 /- Decision Resou...sory firms for pharmaceutical and,healthcare issue...ffers,improvement in patient compared to Sanofi-Av...
(Date:5/15/2008)...y 15 /- Omega 3 fatty acids bound to,... a credible natural,alternative and may have benef...nt in vivo French study reveals. While several stu...n hyperactivity, French researchers have,hypothesi... effects on,impulse control., These research find...
Breaking Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Ceremeds OSTENE 28R 29 Improves Bone Fusion and Healing After Surgery New Study Shows 2045 1Ceremeds OSTENE 28R 29 Improves Bone Fusion and Healing After Surgery New Study Shows 2045 2Ceremeds OSTENE 28R 29 Improves Bone Fusion and Healing After Surgery New Study Shows 2045 3ADVENTRX Pharmaceuticals to Present at the Rodman 26 Renshaw 5th Annual Global Healthcare Conference 5333 1Chiltern Announces New Expansion in Portugal 19137 1Chiltern Announces New Expansion in Portugal 19137 2Providence Holy Cross Medical Center Ignores Community Environmental Concerns With Planned Expansion of Mission Hills Facility 19133 1Providence Holy Cross Medical Center Ignores Community Environmental Concerns With Planned Expansion of Mission Hills Facility 19133 2
...a from XL880, Phase II data from XL999 studies,sch...ns -, SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswir...t data from clinical trials of,the company,s inves...nted at the 2007 American Society of Clinical Onco...ne 1 to 5 in Chicago,Illinois. , , -- Data fro...
...y 31, 2007 /PRNewswire-FirstCall/ -- Lev,Pharmaceu...day that,it has completed patient treatment in the...ial of C1-esterase inhibitor (C1-INH) for,heredita...d CHANGE,examined and evaluated the efficacy and ...cute HAE attacks and as,prophylactic treatment to ...
Other Medicine Technology:Six Abstracts Featuring Exelixis Compounds Accepted At ASCO,Conference 2Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of,C1-Esterase Inhibitor for Hereditary Angioedema 2Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of,C1-Esterase Inhibitor for Hereditary Angioedema 3Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of,C1-Esterase Inhibitor for Hereditary Angioedema 4
HDL Cholesterol (PEG) Precip. Reagent + 5 ml of 50 mg/dl cholesterol std.
Cholesterol/HDL with 200 tests.
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol
For the quantitative determination of High Density Lipoprotein in serum. Available in liquid type. Polyethylene glycol (6000) precipitating reagent. Linearity: 200 mg/dl.
Medicine Products: